Ken Griffin’s Elicio Therapeutics ELTX Stock Holding History

Ken Griffin’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$171K	Buy	+15,978	New	+$154K	﹤0.01%	11569
2024 Q4	–	Sell	-12,856	Closed	-$64.7K	–	14710
2024 Q3	$64.7K	Buy	+12,856	New	+$57K	﹤0.01%	11635
2024 Q1	–	Sell	-14,005	Closed	-$117K	–	14746
2023 Q4	$117K	Sell	14,005 -2,201	-14%	-$14.3K	﹤0.01%	10738
2023 Q3	$137K	Buy	+16,206	New	+$154K	﹤0.01%	10496
2022 Q4	–	Sell	-1,468	Closed	-$14K	–	14981
2022 Q3	$14K	Sell	1,468 -4,548	-76%	-$47.5K	﹤0.01%	12175
2022 Q2	$69K	Buy	+6,016	New	+$96.1K	﹤0.01%	11713
2021 Q3	–	Sell	-2,386	Closed	-$311K	–	13971
2021 Q2	$311K	Sell	2,386 -1,110	-32%	-$160K	﹤0.01%	11171
2021 Q1	$631K	Buy	+3,496	New	+$675K	﹤0.01%	9171

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ken Griffin's ELTX Position: Q1 2026 in Review

Ken Griffin opened a new position in Elicio Therapeutics (ELTX) in Q1 2026: 15,978 shares worth $171K. The stake represents ﹤0.01% of the portfolio and ranks #11569 among its holdings. This is a return to the name: Ken Griffin previously reported a position in ELTX as recently as Q3 2024.

Ken Griffin first reported a position in ELTX in Q1 2021 and has held it in 8 quarters since. The position peaked at $631K in Q1 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Ken Griffin held 15,978 shares of Elicio Therapeutics worth $171K as of Q1 2026.
Elicio Therapeutics was a new Ken Griffin position in Q1 2026.
Elicio Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #11569 holding.
Ken Griffin first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 8 quarters since.
Ken Griffin's Elicio Therapeutics position peaked at $631K in Q1 2021.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.